Next-generation liquid biopsy detects nano-sized signs of breast cancer in early-stage patients
A USC-led team of researchers finds remarkable results with the blood test in a small group of patients.
A USC-led team of scientists has found indications that a special blood test called a liquid biopsy could determine whether a patient has breast cancer at its early stage and if that cancer is unlikely to return.
The high-definition comprehensive liquid biopsies are conducted using a standard blood draw from the arm of a patient in a doctors office. Once in the laboratory, the sample is examined for signs of cancer.
The study demonstrating the liquid biopsy results for early breast cancer detection was published on Sept. 27 in Natures npj Breast Cancer journal. The work was a collaboration between USC, Billings Clinic, Duke University, Epic Sciences and the USC Norris Comprehensive Cancer Center. The results raise hopes that one day doctors could detect breast cancer in patients with a simple blood draw.
The researchers at the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) are cautiously optimistic about their findings. They are eager to test and see whether the results will be proven in larger clinical trials to demonstrate the benefit of the method for patients everywhere.
Its an amazing opportunity to change how early breast cancer detection is being done with a simple blood draw.
Peter Kuhn, USCs CSI-Cancer
Its an amazing opportunity to change how early breast cancer detection is being done with a simple blood draw, but it’s only a research outcome at this point and we still need to demonstrate clinical benefit, said Peter Kuhn, a USC cancer physicist who directs CSI-Cancer.
Breast cancer is the most prevalent form of cancer in the world, affecting 1 in 8 women over their lifetime.
Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique along with a tissue biopsy has become the standard way for doctors to check patients for breast cancer.
Breast cancer detection: Mammography isnt 100% accurate
But mammography is not 100% accurate and its detection can be impeded by healthy dense tissue. Mammographys sensitivity to breast cancer is about 87%, according to the Breast Cancer Surveillance Consortium. And for some women, mammograms are not accessible, especially those living in poor isolated communities that have no clinics or hospitals. Other women simply do not get a regular mammogram.
But a tissue biopsy also is not a foolproof method. Although it can reveal information about the tumor, it has limitations. Doctors can sample only a small area and may fail to capture the full extent of the tumor. A tissue biopsy is also invasive and painful.
Combined, the drawbacks for diagnosis with mammograms and tissue biopsies mean some patients are not diagnosed until the cancer has grown and spread. New methodologies such as CSI-Cancers liquid biopsy can bring a complementary toolset into clinical practice.
For the study, Kuhn and his team worked with 100 breast cancer patients some early and some late stage and 40 patients without breast cancer from April 2013 through January 2017. The work was conducted at clinical sites including at the USC Norris cancer center at the Keck School of Medicine of USC; the Billings Clinic in Montana; the Duke University Cancer Institute in Durham, N.C.; and the City of Hope Comprehensive Cancer Center in Duarte.
The team tested a theory that the high-definition liquid biopsy could detect multiple cancer biomarkers, including the so-called oncosomes nano-sized, membraned cargo carriers that enrich the bodys environment for cancer growth. These oncosomes are secreted by cancer cells as the group has shown previously.
The news here is that we found the vast majority of early-stage breast cancer patients have these oncosomes at very robust levels, said Kuhn, a Deans Professor at the USC Dornsife College of Letters, Arts and Sciences and cancer physicist. Theyre about 5-10 microns in diameter, about the size of a cell. We first identified these large vesicles in prostate cancer about a year-and-a-half ago and showed that they are related to the cancer. They are hiding in plain sight.
A future diagnostic tool for breast cancer detection?
If further studies produce similar results, it could mean that the next generation high-definition liquid biopsy may become a diagnostic tool for early breast cancer detection and other cancers, he said. The test also could inform patients who have been treated for cancer that they will most likely remain cancer-free.
Typically, Im the bearer of bad news. I say, You have cancer in your blood, Kuhn said. But a test like this could give hope that if there is a sign of cancer, we can find it very early and improve treatment and survival.
Kuhns co-authors included from USC: Sonia Maryam Setayesh, Olivia Hart, Amin Naghdloo and Nikki Higa, Anand Kolatkar, as well as Nicholas Matsumoto, Rafael Nevarez, James B. Hicks, Jeremy Mason, Stephanie N. Shishido at USC Michelson. Other researchers were Jorge Nieva and Janice Lu of the USC Norris Center at Keck Medicine of USC, Shelley Hwang of Duke University School of Medicine, Kathy Wilkinson and Michael Kidd of Billings Clinic, as well as Amanda Anderson of Epic Sciences in San Diego.
The study was funded by grants from Breast Cancer Research Foundation; USC Norris Comprehensive Cancer Center; the National Cancer Institute; National Institutes of Health; Kalayil and Leela Chacko, Fellowship; Winnie and James Hart Endowed Fellowship; USC Dornsife Student Opportunities for Academic Research Fellowship; Vassiliadis Research Fund; Vicky Joseph Research Fund; Hart Family Research Fund; The Hsieh Family Foundation; Sandy Borden Thielicke; Jennifer B. and Gregory A. Ezring; Rochika and Kenny Dewan; Andy Perlman; Neil and Anjini Desai; Mamak and Mahmood Razavi Research Fund; Susan Pekarovics; Anila P. Bhagavatula; Giorgio De Santis; Thuy Thanh Truong; Cheryl Faillace; Wayne R. Green Fund; Armstrong McDonald Foundation; Ms. Margaret Turney Hulter Funds; Suzanne B. Borden Fund; and Mr. and Mrs. Stanley A. Mayer Fund.